Ad hoc announcement pursuant to Art. 53 LRAllschwil, Switzerland, December 16, 2024Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a ...

in product revenues last fiscal year - with the bulk coming from antifungal therapy Cresemba (isavuconazole). There are nearly 120,000 S. aureus bloodstream infections in the US, according to 2017 ...

In 2023, Basilea reported CHF 180 million ($200 million) in sales of Zevtera and antifungal therapy Cresemba (isavuconazole), with the latter drug accounting for the bulk of that figure.

Valley fever, or coccidioidomycosis, is an infection caused by a fungus called coccidioides. It's also known as San Joaquin Valley fever or desert rheumatism. Valley fever is the first stage of ...

At close: 4 December at 16:00:00 GMT-5 ...